Q3 EPS Forecast for Amicus Therapeutics Lifted by Analyst

Key Points

• Analysts at Zacks Research have raised their Q3 2026 earnings per share (EPS) estimate for Amicus Therapeutics to $0.12, up from the previous forecast of $0.11, maintaining a "Strong-Buy" rating on the stock.
• Several analysts have upgraded their ratings on the stock recently, with Needham & Company and Wall Street Zen changing their ratings to "buy" with a price target of $14.00.
• Amicus Therapeutics' stock currently has an average rating of "Moderate Buy" and an average target price of $15.78, reflecting investor confidence despite some analysts issuing a "sell" rating.

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Investment analysts at Zacks Research raised their Q3 2026 EPS estimates for Amicus Therapeutics in a research note issued on Tuesday, October 7th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $0.12 per share for the quarter, up from their previous forecast of $0.11. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Amicus Therapeutics' current full-year earnings is $0.15 per share. Zacks Research also issued estimates for Amicus Therapeutics' Q1 2027 earnings at $0.11 EPS, Q2 2027 earnings at $0.13 EPS, Q3 2027 earnings at $0.16 EPS and FY2027 earnings at $0.60 EPS.

Other analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Amicus Therapeutics in a research note on Saturday, September 27th. Needham & Company LLC raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating and set a $14.00 price objective on the stock in a research note on Thursday, September 18th. Wall Street Zen raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, September 20th. Finally, Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $15.78.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $8.16 on Wednesday. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The stock has a market capitalization of $2.52 billion, a price-to-earnings ratio of -67.99 and a beta of 0.56. Amicus Therapeutics has a 1-year low of $5.51 and a 1-year high of $12.65. The firm's 50-day moving average price is $7.62 and its two-hundred day moving average price is $6.90.

Institutional Trading of Amicus Therapeutics

Several hedge funds have recently modified their holdings of FOLD. Vestal Point Capital LP boosted its stake in Amicus Therapeutics by 178.4% in the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company's stock valued at $68,187,000 after acquiring an additional 7,625,000 shares during the last quarter. Nuveen LLC bought a new position in Amicus Therapeutics in the first quarter valued at approximately $28,741,000. Norges Bank bought a new position in Amicus Therapeutics in the second quarter valued at approximately $18,540,000. Assenagon Asset Management S.A. boosted its stake in Amicus Therapeutics by 641.2% in the second quarter. Assenagon Asset Management S.A. now owns 3,533,854 shares of the biopharmaceutical company's stock valued at $20,249,000 after acquiring an additional 3,057,072 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Amicus Therapeutics by 635.1% in the first quarter. Millennium Management LLC now owns 3,359,389 shares of the biopharmaceutical company's stock valued at $27,413,000 after acquiring an additional 2,902,375 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.